<DOC>
	<DOCNO>NCT02133508</DOCNO>
	<brief_summary>This multicenter , retrospective prospective observational , cohort study examine effect second-line Tarceva treatment long response NSCLC patient wild type unknown EGFR status . Patients observed start treatment 8 month death . The extension retrospective versus prospective observation depend lag date patient enrollment date begin erlotinib therapy .</brief_summary>
	<brief_title>A Study Examining Long Response Lung Cancer Patients Treated With Tarceva ( Erlotinib )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients stage IIIb IV NSCLC Patients age &gt; /= 18 year Secondline treatment Tarceva start study inclusion SD response , CR/PR accord RECIST v. 1.1 , last least 4 week know presence epidermal growth factor receptor ( EGFR ) mutation participation clinical trial Tarceva study observation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>